Smith K A, Chernova O B, Groves R P, Stark M B, Martínez J L, Davidson J N, Trent J M, Patterson T E, Agarwal A, Duncan P, Agarwal M L, Stark G R
Imperial Cancer Research Fund, London, United Kingdom.
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1816-21. doi: 10.1073/pnas.94.5.1816.
Rodent cells resistant to N-phosphonacetyl-L-aspartate (PALA) invariably contain amplified carbamyl-P synthetase/aspartate transcarbamylase/dihydro-orotase (CAD) genes, usually in widely spaced tandem arrays present as extensions of the same chromosome arm that carries a single copy of CAD in normal cells. In contrast, amplification of CAD is very infrequent in several human tumor cell lines. Cell lines with minimal chromosomal rearrangement and with unrearranged copies of chromosome 2 rarely develop intrachromosomal amplifications of CAD. These cells frequently become resistant to PALA through a mechanism that increases the aspartate transcarbamylase activity with no increase in CAD copy number, or they obtain one extra copy of CAD by forming an isochromosome 2p or by retaining an extra copy of chromosome 2. In cells with multiple chromosomal aberrations and rearranged copies of chromosome 2, amplification of CAD as tandem arrays from rearranged chromosomes is the most frequent mechanism of PALA resistance. All of these different mechanisms of PALA resistance are blocked in normal human fibroblasts.
对N-膦酰基乙酰-L-天冬氨酸(PALA)具有抗性的啮齿动物细胞总是含有扩增的氨甲酰磷酸合成酶/天冬氨酸转氨甲酰酶/二氢乳清酸酶(CAD)基因,通常以广泛间隔的串联阵列形式存在,作为在正常细胞中携带CAD单拷贝的同一染色体臂的延伸。相比之下,CAD的扩增在几种人类肿瘤细胞系中非常罕见。染色体重排最少且2号染色体未重排拷贝的细胞系很少发生CAD的染色体内扩增。这些细胞通常通过一种机制对PALA产生抗性,该机制增加天冬氨酸转氨甲酰酶活性而不增加CAD拷贝数,或者它们通过形成等臂染色体2p或保留额外的2号染色体拷贝来获得额外的一份CAD拷贝。在具有多个染色体畸变和2号染色体重排拷贝的细胞中,来自重排染色体的串联阵列形式的CAD扩增是PALA抗性最常见的机制。所有这些不同的PALA抗性机制在正常人成纤维细胞中均被阻断。